PacBio Logo
US69404D1081
A1C3EQ
PACB

PacBio

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 0,86 (-23,89%). A mediana é € 0,86 (-23,89%).

Comprar
  9
Manter
  8
Vender
  1

  • PacBio: clinical growth offsets short-term headwinds

    PacBio reported Q2 revenue of $39 million and saw clinical consumables growth of 67%, but cut its full-year guidance to about $160 million due to delayed rollout of SPRQ‑Nx chemistry and higher compute costs. The company announced a CEO transition to Mark Van Oene, workforce reductions and cost cuts to boost efficiency and realize annual savings of $15–20 million. Large initiatives like the 100,000-sample contract with GeneDx and demand for long-read sequencing support the long-term outlook; the target is positive cash flow in 2028, assuming the next instrument generation launches successfully, compute costs decline and customers migrate to SPRQ‑Nx. » Mais em de.investing.com


  • PacBio names Mark Van Oene CEO with immediate effect

    PacBio’s board of directors has appointed Mark Van Oene, previously chief operating officer, as president and chief executive officer and added him to the board. He succeeds Christian Henry, who resigned after six years as CEO and will remain with the company as an advisor through the end of 2026. Van Oene, who joined PacBio in 2021, is expected to drive commercialization, product development, the expansion of HiFi sequencing, and the strengthening of the clinical and diagnostic markets. » Mais em de.investing.com


  • PacBio introduces SPRQ-Nx chemistry and lowers list price per genome to $345

    PacBio has begun worldwide shipping of the SPRQ-Nx sequencing chemistry and reusable SMRT cells for the Revio platform, cutting the list price per genome to $345 and allowing enterprise pricing below $300. SPRQ-Nx enables repeated use of SMRT cells, improves methylation detection, and—according to beta tests—delivers higher yield and lower error rates than the previous chemistry. DeepConsensus updates, partly developed with Google’s AlphaEvolve, and new deep-learning models for epigenetics will be available via software upgrades and reagent kits for existing Revio systems; the chemistry is slated to be offered for Vega by the end of 2026. » Mais em de.investing.com

Em 2022, PacBio já distribuiu € 0,59 em dividendos. A última distribuição ocorreu em agosto de 2022.

Dados financeiros da empresa

No último trimestre, PacBio registou receitas de € 34,18 mi e um ganho líquido de -€ 39,2 mi
(EUR) junho de 2026
YoY
Receitas 34,18 mi 1,30%
Ganho bruto 11,07 mi 11,11%
Ganho líquido -39,2 mi 10,20%
EBITDA -33,34 mi 10,47%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 353,56 mi
Número de ações
310,6 mi
Máximo/mínimo de 52 semanas
€ 2,35 - € 0,92
Dividendos Não
Beta
2,31
PER (PE Ratio)
-3,07
PEG (PEG Ratio)
-0,04
P/VC (PB Ratio)
-12,35
P/V (PS Ratio)
2,57

Perfil da empresa

Pacific Biosciences of California, Inc. entwirft, entwickelt und fertigt Sequenzierungssysteme zur Lösung genetisch komplexer Probleme. Das Unternehmen bietet PacBio-Systeme an, mit denen biochemische Sequenzierungsreaktionen durchgeführt, überwacht und analysiert werden; Verbrauchsprodukte, einschließlich Einzelmolekül-Echtzeitzellen (SMRT), und verschiedene Reagenzienkits, die für bestimmte Arbeitsabläufe entwickelt wurden, wie z. B. Template-Preparation-Kits zur Umwandlung von DNA in SMRTbell-Doppelstrang-DNA-Bibliotheksformate, einschließlich molekularbiologischer Reagenzien, wie Ligase, Puffer und Exonukleasen. Es bietet auch Bindungskits an, wie z. B. modifizierte DNA-Polymerase, die zur Bindung von SMRTbell-Bibliotheken an die Polymerase in Vorbereitung auf die Sequenzierung verwendet wird; und Sequenzierungskits umfassen Reagenzien, die für die Echtzeit-Sequenzierung am Gerät erforderlich sind, einschließlich der phospholinked Nukleotide. Das Unternehmen beliefert Forschungseinrichtungen, kommerzielle Labors, Genomzentren, öffentliche Gesundheitslabors, Krankenhäuser und klinische Forschungsinstitute, Auftragsforschungsinstitute und akademische Einrichtungen, pharmazeutische Unternehmen und landwirtschaftliche Unternehmen. Es vermarktet seine Produkte über einen Direktvertrieb in Nordamerika und Europa sowie über Vertriebspartner in Asien, Europa, dem Nahen Osten, Afrika und Lateinamerika. Pacific Biosciences of California, Inc. hat eine Entwicklungs- und Vermarktungsvereinbarung mit Invitae Corporation. Das Unternehmen war früher als Nanofluidics, Inc. bekannt und änderte 2005 seinen Namen in Pacific Biosciences of California, Inc. um. Pacific Biosciences of California, Inc. wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Menlo Park, Kalifornien.

Nome
PacBio
CEO
Mark Van Oene
Sede Menlo Park, ca
EUA
Site
Setor
Cuidados de saúde
Indústria
Ciências da vida: ferramentas e serviços
Entrada em bolsa
27/10/2010
Colaboradores 485

Análise aprofundada

Símbolos de ticker

Bolsa Símbolo
NASDAQ
PACB
Frankfurt
P09.F
Düsseldorf
P09.DU
München
P09.MU
🍪

Parqet  utiliza cookies. Saber mais